1. Phase I and pharmacokinetic study of docetaxel combined with melphalan and carboplatin, with autologous hematopoietic progenitor cell support, in patients with advanced refractory malignancies 
Yago Nieto, Elizabeth J. Shpall, Scott I. Bearman, Peter A. McSweeney, Pablo J. Cagnoni, Steve Matthes, Dan Gustafson, Michael Long, Anna E. Barón, Roy B. Jones 
Biology of Blood and Marrow Transplantation 
Volume 11, Issue 4, Pages (April 2005)
DOI: /j.bbmt
Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

2. Figure 1
Clinical neuropathy score before and at different times after HDC in patients treated at the MTD (n = 26).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

3. Figure 2
Linear correlation between docetaxel AUC and dose (r = 0.66; P < .001).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

4. Figure 3
Pharmacodynamic correlations of docetaxel. A, Correlation between peripheral neuropathy and AUC (r = 0.6; P < .0001). B, Correlation between stomatitis and AUC (r = 0.4; P < .01).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions

5. Figure 4 Kaplan-Meier EFS and OS curves (all patients; n = 59).
Biology of Blood and Marrow Transplantation  , DOI: ( /j.bbmt )
Copyright © 2005 American Society for Blood and Marrow Transplantation Terms and Conditions